Compare MFA & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MFA | ESPR |
|---|---|---|
| Founded | 1997 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 976.0M | 898.5M |
| IPO Year | N/A | 2013 |
| Metric | MFA | ESPR |
|---|---|---|
| Price | $9.39 | $3.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $10.96 | $6.67 |
| AVG Volume (30 Days) | 1.3M | ★ 4.8M |
| Earning Date | 02-18-2026 | 11-06-2025 |
| Dividend Yield | ★ 15.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.86 | N/A |
| Revenue | $279,011,000.00 | ★ $303,802,000.00 |
| Revenue This Year | N/A | $26.11 |
| Revenue Next Year | $3.18 | N/A |
| P/E Ratio | $10.98 | ★ N/A |
| Revenue Growth | N/A | ★ 2.83 |
| 52 Week Low | $7.85 | $0.69 |
| 52 Week High | $11.08 | $4.13 |
| Indicator | MFA | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 44.51 | 54.66 |
| Support Level | $9.32 | $3.63 |
| Resistance Level | $9.52 | $3.89 |
| Average True Range (ATR) | 0.17 | 0.19 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 20.80 | 43.00 |
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.